Biochemie GmbH.
!S!WCRTESTINPUT000000!E!
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biochemie GmbH.
Abingworth Adds Stakes To Gilead’s Trodelvy Gamble
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.
BD To Pay $85M To Resolve Alaris Class-Action Claims
Becton, Dickinson and Company has agreed to pay $85m to resolve class-action complaints related to a 2020 recall of Alaris infusion pumps.
Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds
Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.
Stock Watch: Lilly’s Emgality Trod A Well-Beaten Path To Clinical Failure
The outcome of any clinical study is uncertain but the choice of active comparator and sometimes even the placebo arm can magnify unpredictability. Emgality’s recent head-to-head failure in migraine is just the latest in a long list of casualties.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice